David Waltz, M.D.
Affiliations: | Children's Hospital Boston, Boston, MA, United States |
Google:
"David Waltz"Parents
Sign in to add mentor| Mary Ellen Wohl | fellowship/program director | 1988-1991 | Children's Hospital Boston |
Children
Sign in to add trainee| Dublifeasa Slattery | fellowship/program director | 1988-2001 | Children's Hospital Boston |
| Hara Levy | fellowship/program director | 1999-2001 | Children's Hospital Boston |
| Debra Boyer | fellowship/program director | 1999-2002 | Children's Hospital Boston |
| Stacy Briggs | fellowship/program director | 2000-2003 | Children's Hospital Boston |
| Lawrence Rhein | fellowship/program director | 2000-2004 | Children's Hospital Boston |
| Yadira Rivera-Sanchez | fellowship/program director | 2001-2004 | Children's Hospital Boston |
| Dennis Rosen | fellowship/program director | 2001-2006 | Children Hospital Boston |
| Christopher Hug | fellowship/program director | 1999-2022 | Children's Hospital Boston |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wainwright C, McColley SA, McNally P, et al. (2023) Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One Allele: A Phase 3, Open-Label Clinical Trial. American Journal of Respiratory and Critical Care Medicine |
| Uluer AZ, MacGregor G, Azevedo P, et al. (2023) Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet. Respiratory Medicine |
| Sutharsan S, McKone EF, Downey DG, et al. (2021) Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. The Lancet. Respiratory Medicine |
| Barry PJ, Mall MA, Álvarez A, et al. (2021) Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes. The New England Journal of Medicine. 385: 815-825 |
| McCoy KS, Heijerman H, Taylor-Cousar JL, et al. (2020) Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet (London, England). 396: 602 |
| Middleton PG, Mall MA, Dřevínek P, et al. (2019) Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. The New England Journal of Medicine. 381: 1809-1819 |
| Heijerman HGM, McKone EF, Downey DG, et al. (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England) |
| Taylor-Cousar JL, Mall MA, Ramsey BW, et al. (2019) Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two alleles. Erj Open Research. 5 |
| McNamara JJ, McColley SA, Marigowda G, et al. (2019) Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet. Respiratory Medicine |
| Davies JC, Moskowitz SM, Brown C, et al. (2018) VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. The New England Journal of Medicine |